InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
April 24 2024 - 7:30AM
InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering
anti-inflammatory therapeutics by targeting the complement system,
today announced that the Company will participate in the Capital
One Securities 1st Annual Biotech/Biopharma Disrupters Event to be
held in New York City.
InflaRx will participate in a panel titled, New
Potential Dermatology Treatments for Psoriasis, Urticaria, and
Alopecia scheduled on May 14, 2024, at 2:30 PM EDT / 8:30 PM
CEST.
About InflaRx
InflaRx GmbH (Germany) and InflaRx
Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx
N.V. (together, InflaRx).
We are a biotechnology company pioneering
anti-inflammatory therapeutics focused on applying our proprietary
anti-C5a and C5aR technologies to discover, develop and
commercialize first-in-class, potent and specific inhibitors of the
complement activation factor known as C5a and its receptor C5aR.
C5a is a powerful inflammatory mediator involved in the progression
of a wide variety of inflammatory diseases. InflaRx’s lead product
candidate, vilobelimab, is a novel, intravenously delivered,
first-in-class, anti-C5a monoclonal antibody that selectively binds
to free C5a and has demonstrated disease-modifying clinical
activity and tolerability in multiple clinical studies in different
indications. InflaRx is also developing INF904, an orally
administered small molecule inhibitor of C5a-induced signaling via
the C5a receptor. InflaRx was founded in 2007, and the group has
offices and subsidiaries in Jena and Munich, Germany, as well as
Ann Arbor, MI, USA. For further information, please visit
www.inflarx.de.
Contacts:
InflaRx N.V. |
MC Services AG |
Jan Medina, CFAVice President, Head of Investor RelationsEmail:
IR@inflarx.de |
Katja Arnold, Laurie Doyle, Dr. Regina LutzEmail:
inflarx@mc-services.eu Europe: +49 89-210 2280U.S.:
+1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “estimate,” “believe,”
“predict,” “potential” or “continue,” among others. Forward-looking
statements appear in a number of places throughout this release and
may include statements regarding our intentions, beliefs,
projections, outlook, analyses and current expectations concerning,
among other things, the receptiveness of GOHIBIC (vilobelimab) as a
treatment for COVID-19 by COVID-19 patients and U.S. hospitals and
related treatment recommendations by medical/healthcare institutes
and other third-party organizations, our ability to successfully
commercialize and the receptiveness of GOHIBIC (vilobelimab) as a
treatment for COVID-19 by COVID-19 patients and U.S. hospitals or
our other product candidates; our expectations regarding the size
of the patient populations for, market opportunity for, coverage
and reimbursement for, estimated returns and return accruals for,
and clinical utility of GOHIBIC (vilobelimab) in its approved or
authorized indication or for vilobelimab and any other product
candidates, under an Emergency Use Authorization and in the future
if approved for commercial use in the U.S. or elsewhere; our
ability to successfully implement The InflaRx Commitment Program,
the success of our future clinical trials for vilobelimab’s
treatment of COVID-19 and other debilitating or life-threatening
inflammatory indications, including pyoderma gangrenosum, and any
other product candidates, including INF904, and whether such
clinical results will reflect results seen in previously conducted
pre-clinical studies and clinical trials; the timing, progress and
results of pre-clinical studies and clinical trials of our product
candidates and statements regarding the timing of initiation and
completion of studies or trials and related preparatory work, the
period during which the results of the trials will become
available, the costs of such trials and our research and
development programs generally; our interactions with regulators
regarding the results of clinical trials and potential regulatory
approval pathways, including related to our Marketing Authorization
Application submission for vilobelimab and our biologics license
application submission for GOHIBIC (vilobelimab), and our ability
to obtain and maintain full regulatory approval of vilobelimab or
GOHIBIC (vilobelimab) for any indication; whether the U.S. Food and
Drug Administration, the European Medicines Agency or any
comparable foreign regulatory authority will accept or agree with
the number, design, size, conduct or implementation of our clinical
trials, including any proposed primary or secondary endpoints for
such trials; our expectations regarding the scope of any approved
indication for vilobelimab; our ability to leverage our proprietary
anti-C5a and C5aR technologies to discover and develop therapies to
treat complement-mediated autoimmune and inflammatory diseases; our
ability to protect, maintain and enforce our intellectual property
protection for vilobelimab and any other product candidates, and
the scope of such protection; our manufacturing capabilities and
strategy, including the scalability and cost of our manufacturing
methods and processes and the optimization of our manufacturing
methods and processes, and our ability to continue to rely on our
existing third-party manufacturers and our ability to engage
additional third-party manufacturers for our planned future
clinical trials and for commercial supply of vilobelimab and for
the finished product GOHIBIC (vilobelimab); our estimates of our
expenses, ongoing losses, future revenue, capital requirements and
our needs for or ability to obtain additional financing; our
ability to defend against liability claims resulting from the
testing of our product candidates in the clinic or, if approved,
any commercial sales; if any of our product candidates obtain
regulatory approval, our ability to comply with and satisfy ongoing
obligations and continued regulatory overview; our ability to
comply with enacted and future legislation in seeking marketing
approval and commercialization; our future growth and ability to
compete, which depends on our retaining key personnel and
recruiting additional qualified personnel; and our competitive
position and the development of and projections relating to our
competitors in the development of C5a and C5aR inhibitors or our
industry; and the risks, uncertainties and other factors described
under the heading “Risk Factors” in our periodic filings with the
SEC. These statements speak only as of the date of this press
release and involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Given these risks, uncertainties
and other factors, you should not place undue reliance on these
forward-looking statements, and we assume no obligation to update
these forward-looking statements, even if new information becomes
available in the future, except as required by law.
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Apr 2024 to May 2024
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From May 2023 to May 2024